Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
10:56am, Thursday, 05'th Feb 2026
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Why Eli Lilly Stock Just Dropped
10:48am, Thursday, 05'th Feb 2026
Hims and Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
10:46am, Thursday, 05'th Feb 2026
Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapprov
Hims And Hers Will Undercut Wegovy Pill With $49 Copy—Novo Stock Shudders
10:10am, Thursday, 05'th Feb 2026
Online pharmaceutical retailer Hims and Hers announced Thursday it will release a much cheaper, compounded version of the Wegovy weight loss pill just over half a year after Novo Nordisk caused its st
VIEW Hims and Hers Health's compounded Wegovy pill offering fuels market jitters
10:06am, Thursday, 05'th Feb 2026
Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month.
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
09:36am, Thursday, 05'th Feb 2026
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock
Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*
09:00am, Thursday, 05'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enablin
Exclusive: Hims and Hers Health launches copy of Wegovy pill at $49
08:33am, Thursday, 05'th Feb 2026
Online telehealth company Hims and Hers Health will begin offering copies of Novo Nordisk's new Wegovy pill at an introductory price of $49 per month, the company said Thursday, about $100 less than t
Hims & Hers launches compounded semaglutide pill as lower-cost weight loss option
07:08am, Thursday, 05'th Feb 2026
Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk...
Reviewing 111 (NASDAQ:YI) & Hims & Hers Health (NYSE:HIMS)
01:18am, Thursday, 05'th Feb 2026
Hims and Hers Health (NYSE: HIMS - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
11:25am, Wednesday, 04'th Feb 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care
09:00am, Wednesday, 04'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a sim
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
06:46pm, Monday, 02'nd Feb 2026
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $26.44, indicating a -2.4% shift from the previous trading day.
Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
04:05pm, Monday, 02'nd Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 202
OMCL or HIMS: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 30'th Jan 2026
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors
